Controversies in Optimal Anemia Management: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Controversies in Optimal Anemia Management : Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference

Babitt, Jodie L. (author)

Eisenga, Michele F. (author)

Haase, Volker H. (author): Uppsala universitet,Institutionen för medicinsk cellbiologi,Vanderbilt University Medical Center; Vanderbilt University School of Medicine,Haase

Kshirsagar, Abhijit V. (author)

Levin, Adeera (author)

Locatelli, Francesco (author)

Małyszko, Jolanta (author)

Swinkels, Dorine W. (author)

Tarng, Der-Cherng (author)

Cheung, Michael (author)

Jadoul, Michel (author)

Winkelmayer, Wolfgang C. (author)

Drüeke, Tilman B. (author)

(creator_code:org_t)

Elsevier, 2021
2021
English.
In: Kidney International. - : Elsevier. - 0085-2538 .- 1523-1755. ; 99:6, s. 1280-1295

Related links:: https://doi.org/10.1...; show more...; https://uu.diva-port... (primary) (Raw object); http://www.kidney-in...; https://urn.kb.se/re...; https://doi.org/10.1...; show less...

Abstract Subject headings

In chronic kidney disease (CKD), anemia and disordered iron homeostasis are prevalent and associated with significant adverse consequences. In 2012, Kidney Disease: Improving Global Outcomes (KDIGO) issued an anemia guideline for managing the diagnosis, evaluation, and treatment of anemia in CKD. Since then, new data have accrued from basic research, epidemiological studies, and randomized trials that warrant a re-examination of previous recommendations. Therefore, in 2019, KDIGO decided to convene two Controversies Conferences to review the latest evidence, explore new and ongoing controversies, assess change implications for the current KDIGO anemia guideline, and propose a research agenda. The first conference, described here, focused mainly on iron-related issues, including the contribution of disordered iron homeostasis to the anemia of CKD, diagnostic challenges, available and emerging iron therapies, treatment targets, and patient outcomes. The second conference will discuss issues more specifically related to erythropoiesis-stimulating agents, including epoetins and hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs). Here we provide a concise overview of the consensus points and controversies resulting from the first conference and prioritize key questions which need to be answered by future research.

By the author/editor: Babitt, Jodie L.; Eisenga, Michele ...; Haase, Volker H.; Kshirsagar, Abhi ...; Levin, Adeera; Locatelli, Franc ...; show more...; Małyszko, Jolant ...; Swinkels, Dorine ...; Tarng, Der-Chern ...; Cheung, Michael; Jadoul, Michel; Winkelmayer, Wol ...; Drüeke, Tilman B ...; show less...

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Clinical Medicin ...; and Urology and Neph ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.